According to a new paper published by the team behind the PsoProtect registry, psoriasis patients treated with biologics are at a lower risk of being hospitalized due to COVID-19 than those treated with non-biologic systemic therapies. Read the full article here:
Factors associated with adverse COVID-19 outcomes in patients with psoriasis - insights from a global registry-based study
Stay informed Join the email list to receive the latest information on psoriasis meetings, manuscripts and research. SUBSCRIBE now available COVID-19 Psoriasis Resource Center Information from around the world on psoriasis and coronavirus to assist dermatologists and the patients they serve explore now
Information from around the world on psoriasis and coronavirus to assist dermatologists and the patients they serve